{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Return to MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
  • Sign In
  • Home
  • Live
  • On-Demand
  • RSS/Grand Rounds
  • Non-Accredited
  • About
  • Contact Us
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

MD Anderson workforce members:  Select "MD ANDERSON LOGIN" and enter your MD Anderson email address and password.

Guests (all other than MD Anderson workforce members): Select "GUEST LOGIN" and enter your email address and password.

MD ANDERSON LOGIN
GUEST LOGIN
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • AA
  • AAS
  • ADN
  • BA
  • BS
  • BSN
  • DDS
  • DMD
  • DMin
  • DNP
  • DO
  • DrPH
  • DVM
  • DVM,PhD
  • EdD
  • JD
  • MA
  • MBA
  • MBBS
  • MBBS,MD
  • MD
  • MD, MBA
  • MD, MPH
  • MD, PhD
  • MDiv
  • MEd
  • MHA
  • MPA
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • Other
  • PharmD
  • PharmD, PhD
  • PhD
  • PsyD
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

22nd Oncology Updates: Advanced and Controversies


LIVESurgerySurgical OncologyOncologyMulti-Disciplinary Oncology
22nd Oncology Updates: Advanced and Controversies Banner

  • Overview
  • Faculty
  • Schedule
  • Brochure
  • Hotel
  • Exhibitors
Add to Calendar 22nd Oncology Updates: Advanced and Controversies 1/16/2026 7:00:00 AM 1/19/2026 12:00:00 PM America/Chicago For More Details: https://mdanderson.cloud-cme.com/OncologyUpdates2026 Description: The 22nd Oncology Updates: Advances in Controversies Conference offers an interactive, multidisciplinary forum designed to address the evolving complexities of solid tumor management. As the treatment landscape rapidly advances, clinicians must remain informed about emerging therapies and their application across various stages of disease. Increasingly, interventions once reserved for advanced cancers are bei... Steamboat Grand Hotel false MM/DD/YYYY


Date & Location
Friday, January 16, 2026, 7:00 AM - Monday, January 19, 2026, 12:00 PM, Steamboat Grand Hotel, Steamboat Springs, CO

Target Audience
Specialties - Colon and Rectal Surgery, Complex General Surgical Oncology, Gynecologic Oncology, Hospice and Palliative Medicine, Medical Oncology, Pathology - Anatomic/Pathology - Clinical, Radiation Oncology, Urology
Professions - Nurse - APRN, Other, Physician (MD or DO), Student or Trainee

Credits
AMA PRA Category 1 Credits™ (19.25 hours), ABS CC (19.25 hours), Medical Ethics/Professional Responsibility (2.50 hours), Non-Physician Attendance (19.25 hours)

Overview
The 22nd Oncology Updates: Advances in Controversies Conference offers an interactive, multidisciplinary forum designed to address the evolving complexities of solid tumor management. As the treatment landscape rapidly advances, clinicians must remain informed about emerging therapies and their application across various stages of disease. Increasingly, interventions once reserved for advanced cancers are being utilized in earlier, potentially curative settings, requiring a deeper understanding of both foundational principles and cutting-edge developments. This conference convenes leading experts from surgical oncology, medical oncology, radiation oncology, pathology, radiology, cancer prevention, and symptom management to explore current challenges, novel therapies, and clinical controversies. Through case-based discussions and evidence-driven presentations, participants will gain the knowledge and skills needed to integrate preclinical and clinical data into practice. The ultimate goal is to equip healthcare professionals with the tools to deliver the highest standard of care to patients with solid tumors.

Objectives
At the conclusion of this activity, learners will be able to:

  1. Applying an evidence-based sequence of surgical, radiation, and systemic therapies, including immunotherapies and molecular-targeted treatments, for solid tumors such as head and neck, gastrointestinal, melanoma, lung, breast, gynecologic, and genitourinary cancers.
  2. Evaluating and selecting optimal treatment strategies for patients across various disease stages, clinical presentations, and comorbidities, using case-based scenarios to guide decision-making.
  3. Integrating preventive strategies, screening protocols, and symptom management into comprehensive oncology care to enhance patient outcomes and quality of life.

Registration

On-site registration for the 22nd Annual Oncology Update: Advances and Controversies, will open at 6:30 AM on Friday, January 16, 2026, and the conference will begin at 7:00 AM. The conference will adjourn at 10:00 am on Monday, January 19, 2025.  Advanced registration is encouraged as space and materials are limited.  Please see registration form for applicable fees.

Advanced registration is encouraged. The deadline for advanced registration is January 5, 2026.

Agenda coming soon!

PORTAL REGISTRATION IS NOW CLOSED, YOU MAY REGISTER ON-SITE.

Registration Fees:

REGISTRATION CATEGORY

BEFORE JAN. 5

After JAN. 5

ON-SITE

Non-MD Anderson Physicians 

$700

$750

$800

MD Anderson Faculty/Physicians

$650

$700

$800

Other Healthcare Professionals 

$400

$450

$500

Oncology Update Guest Ticket (Meals Only)

$300

$350

$350

Scientists

$650

$650

$700

Telephone registrations are not accepted.

We accept the following forms of payment:
Credit Cards (MasterCard, VISA, and American Express)
Check (Payable to The University of Texas MD Anderson Cancer Center; through U.S. banks only)

Mail checks to:
   
Continuing Professional Education (CPE) – Unit 1781
   The University of Texas MD Anderson Cancer Center
   P.O. Box 301407
   Houston, Texas 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on your profile during the process. 
 
Refund/Cancellation Policy
The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 5, 2026.  No refunds will be granted after this date.  The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. 

The Department of Continuing Professional Education (CPE) reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of the CPE is limited to the registration fee. CPE will refund the full registration fee. 

CPE reserves the right to limit the number of participants in an activity and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

Special Assistance or Additional Information
Contact Continuing Professional Education/Activity Management at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected].

Evaluation
A course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status.  Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. 


Accreditation

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 19.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity for  a maximum of 2.50 credit(s) of education in medical ethics and/or professional responsibility. 



American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.



Additional Information

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

 


Accommodations / Ski Rentals/Lift Tickets / Shuttle Service

THE STEAMBOAT GRAND HOTEL
A block of rooms has been reserved for conference attendees at the Steamboat Grand Hotel, 2300 Mt. Werner Circle, Steamboat Springs, CO 80487

Reservations & Hotel Main Phone: 877-269-2628.  Early hotel reservation is suggested.

When you make reservations, be sure to mention the MD Anderson Cancer Center 2026 to be assured of receiving the special meeting rate.

Reservations and deposits received after December 16, 2025, will be confirmed if space is available and at currently published hotel guest room rates
Reservations Link

Room Deposit: rooms are guaranteed 30 days prior to arrival by taking a full deposit of the entire stay. Upon the taking of the deposit all reservations are unchangeable.  If cancelled the deposit is non-refundable. 

Room Tax and Fees: taxes are 20.4% of the room cost, and resort fee is 7% (plus 20.4% tax) currently totaling 28.828%. Taxes and resort fees are per room, per night, and are subject to change without notice. 

Ski Rentals/Lift Ticket Discounts:
Be sure to secure your tickets by calling central reservations: 877-269-2628.
You can also visit the Steamboat Grand Reservations site for additional options: https://group.steamboatgrand.com/products/lift-tickets

Lift Ticket (only): https://group.steamboatgrand.com/packages/package/86481/?code=MDAN26

Additional Hotels - Click on each property below for more information:


Ptarmigan Inn / Gravity Haus www.gravityhaus.com

Sheraton

West Condos

For more options, use the Steamboat.com link below to browse local lodging by neighborhood. The Steamboat Grand is in the "Base Area" neighborhood, so selecting the BASE AREA as the location will show the closest properties to The Grand!

Steamboat.com
_________________

Shuttle Transportation

Steamboat Express Shuttle
Phone: 970-728-6000

Storm Mountain Express
https://stormmountainexpress.com/
Conference Code:  MDACC
Telephone: 970-879-1963

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Eric Gagneaux
Continuing Education Planner
MD Anderson Cancer Center
Activity Administrator
Nothing to disclose
Dhanalakshmi Koyyalagunta, MD
Professor
University of Texas MD Anderson Cancer Center
CE Reviewer
Nothing to disclose
Brian K. Bednarski, MD
Associate Professor
MD Anderson Cancer Center
Co-Director, Content Reviewer, Faculty
Nothing to disclose
Merrick I. Ross, MD, FACS
Professor of Surgery
UT MD Anderson Cancer Center
Course Director, Faculty
Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Honoraria-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)
Rodabe N. Amaria, MD
Associate Professor, Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-KSQ|Grant or research support-Erasca|Grant or research support-Erasca|Consulting Fee-Obsidian |Grant or research support-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Grant or research support-Bristol-Myers Squibb Company (Relationship has ended)|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-Iovance (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Obsidian|Grant or research support-OnKure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-TIL Working Group|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended)
Brian D. Badgwell, MD
Professor of Surgery
MD Anderson Cancer Center
Faculty
Advisor-AstraZeneca US (Relationship has ended)|Advisor-Bristol-Myers Squibb Company (Relationship has ended)
Kelly K Bree, MD
Assistant Professor
MD Anderson Cancer Center
Faculty
Nothing to disclose
Matthew T. Campbell, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Advisor-Eisai, Inc. (Relationship has ended)|Advisor-Astellas Scientific and Medical Affairs, Inc.|Advisor-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Speakers Bureau-Curio Science (Relationship has ended)|Speakers Bureau-MJH Life Sciences (Relationship has ended)|Advisor-Pfizer Inc. (Relationship has ended)|Consulting Fee-Exelixis (Relationship has ended)|Grant or research support-Seattle Genetics, Inc. (Relationship has ended)|Advisor-AXDev (Relationship has ended)|Grant or research support-Exelixis|Grant or research support-Pfizer Inc.|Grant or research support-Janssen Biotech, Inc. (Relationship has ended)|Grant or research support-Aravive (Relationship has ended)|Grant or research support-AstraZeneca US
Brian F. Chapin, MD
Professor
MD Anderson Cancer Center
Faculty
Advisor-Johnson & Johnson (any division)|Grant or research support-Regeneron Pharmaceuticals, Inc.|Advisor-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Advisor-Pfizer Inc.|Advisor-Janssen Biotech, Inc.
Ana Ciurea, MD
MD Anderson Cancer Center
Faculty
Nothing to disclose
Jordan Cloyd, MD
Dr
The Ohio State University
Faculty
Nothing to disclose
Lorenzo Cohen, PhD
Professor and Director
MD Anderson Cancer Center
Faculty
Consulting Fee-ReHeva Biosciences (Relationship has ended)|Royalties or Patent Beneficiary-Penguin Random House|Advisor-Complement 1
Keith Delman, MD
Dr.
Emory University SOM
Faculty
Nothing to disclose
Steven J. Frank, MD
Professor
MD Anderson Cancer Center
Faculty
Consulting Fee-Boston Scientific Corporation|Membership on Advisory Committees or Review Panels, Board Membership, etc.-C4 Imaging|Grant or research support-Hitachi Medical Systems America, Inc.|Grant or research support-Affirmed Pharma (Relationship has ended)|Consulting Fee-IBA
Jeffrey E. Gershenwald, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Other: Consultant/Advisor-Philogen
Don L. Gibbons, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Advisor-Lilly USA, LLC (Relationship has ended)|Consulting Fee-Aktis Oncology|Grant or research support-NGM Biopharmaceuticals (Relationship has ended)|Grant or research support-Boehringer Ingelheim|Consulting Fee-Menarini Ricerche|Consulting Fee-Onconova (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-Sanofi US (Relationship has ended)|Grant or research support-Boehringer Ingelheim|Grant or research support-Mirati
Sharon H. Giordano, MD, FASCO
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Isabella C. Glitza, MD
Associate Professor
UT MD Anderson Cancer Center
Faculty
Consulting Fee-Novartis Pharmaceuticals Corporation|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Pfizer Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division)
Justin R. Gregg, MD
Assistant Professor
UT MD Anderson Cancer Center
Faculty
Advisor-Bayer HealthCare Pharmaceuticals, Inc.|Advisor-Johnson & Johnson (any division) (Relationship has ended)
Neil D. Gross, MD
Professor
MD Anderson Cancer Center
Faculty
Grant or research support-Regeneron Pharmaceuticals, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Replimune (Relationship has ended)|Paid consultant-Genzyme Corporation|Membership on Advisory Committees or Review Panels, Board Membership, etc.-PDS Biotechnology|Paid consultant-Intuitive Surgical, Inc. (Relationship has ended)|Paid consultant-Merck Sharp & Dohme Corp. (any division)|Paid consultant-Dragonfly Therapeutics (Relationship has ended)
John V. Heymach, MD
Chair, Thoracic-Head & Neck Med Onc
The University of Texas MD Anderson Cancer Center
Faculty
Advisor-AstraZeneca US|Advisor-Bayer HealthCare Pharmaceuticals, Inc.|Advisor-BioNTech|Advisor-EMD Serono Inc.|Advisor-Boehringer Ingelheim|Advisor-Spectrum Pharmaceuticals, Inc. (Relationship has ended)|Advisor-Takeda|Advisor-DAVA Oncology|Advisor-Bristol-Myers Squibb Company|Advisor-Jazz Pharmaceuticals|Advisor-ModeX|Advisor-Regeneron Pharmaceuticals, Inc.|Consulting Fee-Janssen Biotech, Inc.|Grant or research support-AstraZeneca US|Grant or research support-Boehringer Ingelheim|Grant or research support-Takeda Pharmaceuticals|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Taiho Oncology, Inc.|Grant or research support-Spectrum Pharmaceuticals, Inc. (Relationship has ended)|Royalties or Patent Beneficiary-Spectrum Pharmaceuticals, Inc.
Wayne L. Hofstetter, MD
Professor
MD Anderson Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Oncolys Advisory Board|Honoraria-Merck Sharp & Dohme Corp. (any division)
Kelly K. Hunt, MD
Professor
MD Anderson Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Armada Health (Relationship has ended)|Honoraria-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Daiichi Sankyo, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Grant or research support-Lilly USA, LLC (Relationship has ended)|Grant or research support-Cairn Surgical|Grant or research support-Lumicell
Rosa F. Hwang, MD, FACS
Professor, Breast Surgical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Matthew H. Katz, MD
Professor, Surgical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Michael P. Kim, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Consulting Fee-PanTher Therapeutics|Consulting Fee-Olympus Corporation of the Americas
Eugene J. Koay, MD
MD Anderson Cancer Center
Faculty
Consulting Fee-RenovoRx (Relationship has ended)|Royalties or Patent Beneficiary-Taylor and Francis LLC|Consulting Fee-iO Life Sciences|Consulting Fee-AstraZeneca US (Relationship has ended)|Grant or research support-Philips (any division) (Relationship has ended)|Grant or research support-GE Healthcare (Relationship has ended)|Consulting Fee-Nanobiotix|Grant or research support-Varian Medical Systems, Inc|Grant or research support-AstraZeneca US
Albert C Koong, MD
Professor
MD Anderson Cancer Center
Faculty
Nothing to disclose
Jeffrey E. Lee, MD
Chair
MD Anderson Cancer Center
Faculty
Nothing to disclose
Bradley C Leibovich, MD, FACS
Mayo Clinic
Faculty
Nothing to disclose
Elizabeth J Lilley, MD, MPH
Brigham and Women's Hospital
Faculty
Nothing to disclose
Jennifer K. Litton, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Heather Lyu, MD
MD Anderson Cancer Center
Faculty
Nothing to disclose
Paul F. Mansfield, MD
Professor of Surgical Oncology
UT MD Anderson Cancer Center
Faculty
Stocks or stock options, excluding diversified mutual funds-Amgen Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Pfizer Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Stryker (any division) (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Medtronic, Inc. (any division)
Surena F. Matin, MD
Professor
UT MD Anderson Cancer Center
Faculty
Consulting Fee-FUJIFILM Medical Systems USA, Inc. (all divisions) (Relationship has ended)|Consulting Fee-MashUp Media (Relationship has ended)|Grant or research support-Urogen|Grant or research support-Ferring Pharmaceuticals Inc.|Consulting Fee-Janssen Biotech, Inc.|Consulting Fee-Johnson & Johnson (any division)|Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Helsinn Therapeutics (U.S.) Inc. (Relationship has ended)
Funda Meric-Bernstam, MD
Chair, Invest. Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-AstraZeneca US|Membership on Advisory Committees or Review Panels, Board Membership, etc.-LOXO-Oncology|Consulting Fee-OnCusp Therapeutics (Relationship has ended)|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zentalis|Consulting Fee-Zymeworks|Grant or research support-Aileron Therapeutics (Relationship has ended)|Grant or research support-AstraZeneca US|Grant or research support-Bayer HealthCare Pharmaceuticals, Inc.|Grant or research support-Calithera (Relationship has ended)|Grant or research support-CytomX Therapeutics (Relationship has ended)|Grant or research support-Curis (Relationship has ended)|Grant or research support-Daiichi Sankyo, Inc.|Grant or research support-Debiopharm|Grant or research support-eFFECTOR Therapeutics|Grant or research support-Genentech, Inc. (Relationship has ended)|Grant or research support-Klus Pharma (Relationship has ended)|Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Puma Pharmaceuticals (Relationship has ended)|Grant or research support-Taiho Oncology, Inc. (Relationship has ended)|Consulting Fee-GT Apeiron (Relationship has ended)|Consulting Fee-Menarini|Consulting Fee-Ecor1 Capital (Relationship has ended)|Consulting Fee-Calibr, a division of Scripps Research|Consulting Fee-LegoChem Bio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Theratechnologies|Honoraria-Dava Oncology (Relationship has ended)|Other: Travel Reimbursement-Dava Oncology (Relationship has ended)|Consulting Fee-Protai|Consulting Fee-Becton Dickinson|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Cybrexa Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Guardant|Consulting Fee-Harbinger Health (Relationship has ended)|Consulting Fee-Mersana (Relationship has ended)|Consulting Fee-Daiichi Sankyo, Inc.|Consulting Fee-Debiopharm|Consulting Fee-eFFECTOR Therapeutics|Consulting Fee-Elevation Oncology|Consulting Fee-Exelixis|Consulting Fee-Incyte Corporation|Consulting Fee-Jazz Pharmaceuticals|Consulting Fee-Ribometrix|Consulting Fee-Tempus|Consulting Fee-Molecular Templates (Relationship has ended)|Other: Travel Reimbursement-European Organisation for Research and Treatment of Cancer (Relationship has ended)|Other: Travel Reimbursement-European Society for Medical Oncology (Relationship has ended)|Other: Travel Reimbursement-Cholangiocarcinoma Foundation (Relationship has ended)|Consulting Fee-Biocartis NV|Consulting Fee-LigaChem Biosciences|Consulting Fee-SystImmune|Consulting Fee-Vir Biotechnology|Membership on Advisory Committees or Review Panels, Board Membership, etc.-go Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Illumen Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kivu Biosciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Seagen
Lavinia P Middleton, MD
Professor of Pathology
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Neema Navai, MD
Associate Prof and Deputy Chair
MD Anderson Cancer Center
Faculty
Advisor-Pfizer Inc.|Advisor-Ferring Pharmaceuticals Inc.
Timothy Newhook, MD
Assistant Professor, Surgical Oncology
MD Anderson Cancer Center
Faculty
Nothing to disclose
Quynh Nhu Nguyen, MD
Associate Professor
University of Texas, M.D. Anderson Cancer Center
Faculty
Nothing to disclose
Nicolas Palaskas, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Kiniksa Pharmaceuticals|Honoraria-Scripps (Relationship has ended)|Consulting Fee-Replimmune
Anisha Patel, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Grant or research support-OnQuality (Relationship has ended)|Consulting Fee-Roche|Grant or research support-Lutris (Relationship has ended)|Paid consultant-Janssen Biotech, Inc.|Grant or research support-Hoth|Paid consultant-Asymmetric|Paid consultant-Lutris|Paid consultant-Erasca|Paid consultant-Synox|Paid consultant-Revolution Medicine
Sapna Patel, MD
Professor of Medicine and Opthalmology
Univ. of Colorado Cancer Center
Faculty
Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Foghorn Therapeutics|Grant or research support-Ideaya|Grant or research support-InxMed|Grant or research support-Lyvgen Biopharma|Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Provectus Biopharmaceuticals|Grant or research support-Seattle Genetics, Inc.|Grant or research support-Syntrix Bio|Grant or research support-TriSalus Life Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Delcath (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ideaya|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-OncoSec (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Replimune (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-TriSalus Life Sciences|Speakers Bureau-Bristol-Myers Squibb Company|Speakers Bureau-Merck Sharp & Dohme Corp. (any division)
Peter Pisters, MD
President
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Victor G Prieto, MD
Professor
MD Anderson Cancer Center
Faculty
Consulting Fee-Myriad (Relationship has ended)|Consulting Fee-Orlucent|Consulting Fee-Castle Biosciences, Inc.
David C. Rice, MD
Professor, Thoracic & Cardiovasc Surgery
MD Anderson Cancer Center
Faculty
Consulting Fee-Intuitive Surgical, Inc.|Consulting Fee-FUJIFILM Medical Systems USA, Inc. (all divisions)
Aysegul Sahin, MD
Professor
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Aaron Shafer, MD
Dr.
MD Anderson Cancer Center
Faculty
Nothing to disclose
Pamela T. Soliman, MD
MD Anderson Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-GlaxoSmithKline|Consulting Fee-Eisai, Inc. (Relationship has ended)
Michael C. Stauder, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Sumit K. Subudhi, MD
Associate Professor
UT MD Anderson Cancer Center
Faculty
Nothing to disclose
Stephen G. Swisher, MD
Division Head
The University of Texas MD Anderson Cancer Center
Faculty
Nothing to disclose
Michael Tetzlaff, MD
Professor
University of California, San Francisco
Faculty
Advisor-Merck Sharp & Dohme Corp. (any division)|Advisor-Regeneron Pharmaceuticals, Inc.|Advisor-Philogen
Hop S. Tran Cao, MD, FACS
Associate Professor - Surgical Oncology
The University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-Intuitive Surgical, Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson (any division)
Jeffrey S. Weinberg, MD
Professor
The University of Texas MD Anderson Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-GT Med Tech (Relationship has ended)
James Welsh, MD
MDACC
Faculty
Grant or research support-Nanobiotix|Consulting Fee-Nanobiotix|Consulting Fee-Kezar Life Sciences (Relationship has ended)|Consulting Fee-Reflexion|Consulting Fee-Nanorobotics (Relationship has ended)|Consulting Fee-Novocure|Grant or research support-Novocure|Consulting Fee-Oncoresponse|Grant or research support-Kiromic (Relationship has ended)|Grant or research support-Gilead Sciences, Inc. (Relationship has ended)|Grant or research support-Hotspot (Relationship has ended)|Grant or research support-Artidis|Grant or research support-Bayer HealthCare Pharmaceuticals, Inc. (Relationship has ended)|Grant or research support-Bristol-Myers Squibb Company (Relationship has ended)|Grant or research support-Takeda (Relationship has ended)|Grant or research support-Varian Medical Systems, Inc|Grant or research support-Sciclone|Grant or research support-Nurix|Consulting Fee-Alpine Immune Sciences|Stocks or stock options, excluding diversified mutual funds-Checkmate|Grant or research support-Genentech, Inc.|Grant or research support-AstraZeneca US
Michael G. White, MD
Assistant Professor
MD Anderson Cancer Center
Faculty
Nothing to disclose
Michael K Wong, MD, PhD, FRCPC
Physician in Chief
Roswell Park Comprehensive Cancer Center
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Sun Pharma|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc.
Candice Gabehart, BA
Office Manager
MD Anderson Cancer Center
Planning Committee Member
Nothing to disclose
Rae B Reynolds, PhD
Associate Director, Surgical Oncology
MD Anderson Cancer Center
Planning Committee Member
Nothing to disclose
Cynthia Scott, BS
Office Manager
UT MD Anderson Cancer Center
Planning Committee Member
Nothing to disclose

Friday, January 16, 2026
Welcome and Opening Remarks
7:00AM - 7:05AM
Merrick I. Ross, MD, FACS

 
SESSION 1: SUPPORTING PATIENTS DURING THEIR CANCER JOURNEY

MODERATOR: Merrick Ross
Evolution in the Management of Grade IV Toxicities*
7:05AM - 7:30AM
Isabella C. Glitza, MD

Session I - Moderator
7:05AM - 7:15AM
Merrick I. Ross, MD, FACS
Dermatological Toxicity
7:30AM - 7:42AM
Anisha Patel, MD

Immune Checkpoint Myocarditis
7:42AM - 7:54AM
Nicolas Palaskas, MD

Refractory Immune-Associated Colitis
7:54AM - 8:06AM
Merrick I. Ross, MD, FACS

Integrative Medicine Support: Improved Quality of Life, Improved Survival Outcome, or Both?
8:06AM - 8:26AM
Lorenzo Cohen, PhD

Palliative Care Decision Making When Caring for Patients with Incurable Disease:
8:26AM - 8:46AM
Elizabeth J Lilley, MD, MPH

Keynote Presentation: Emerging Roles for AI in Oncology
8:46AM - 9:06AM
Heather Lyu, MD

Dermatology Case Discussions Q&A
9:06AM - 9:30AM

 
Non-CE Satellite Symposium

Non-CE Satellite Symposium
9:45AM - 10:30AM

Attendance Optional
Location: Burgess Creek


 
Non-CE Satellite Symposium

Non-CE Satellite Symposium
3:15PM - 4:00PM

Attendance Optional
Location: Burgess Creek


 
SESSION 2: THE BEST OF 2025: PRACTICE CHANGING TRIALS / RESULTS

MODERATOR: Merrick Ross
Renal Cell and Urothelial Cancer
4:15PM - 4:33PM
Matthew T. Campbell, MD
Session 2 - Moderator
4:15PM - 4:25PM
Merrick I. Ross, MD, FACS

Gynecological Oncology
4:33PM - 4:51PM
Pamela T. Soliman, MD
Brachytherapy for Metastatic Brain Disease
4:51PM - 5:09PM
Jeffrey S. Weinberg, MD

Radiation for Head and Neck Cancer
5:09PM - 5:20PM
Steven J. Frank, MD

 
SESSION 3: BIOMARKER DIRECTED MANAGEMENT / THERAPY

MODERATOR: Funda Meric-Bernstam
Matching Novel Drug Delivery Systems to Actionable Targets
5:20PM - 5:35PM
Funda Meric-Bernstam, MD

Session 3 - Moderator
5:20PM - 5:30PM
Funda Meric-Bernstam, MD
Evolving Role for Circulating Tumor DNA (ctDNA) Assays of MRD - Colorectal Cancer
5:35PM - 5:47PM
Timothy Newhook, MD

A Critical Look at Multi-Cancer Early Detection (MCED) Testing*
5:47PM - 6:02PM
Jennifer K. Litton, MD

 
SESSION 4: NEOADJUVANT SYMPOSIUM: NEWCOMERS AND CONTROVERSIES

MODERATOR: Merrick Ross
Neoadjuvant Revolution
6:15PM - 6:27PM
Merrick I. Ross, MD, FACS

Session 4 - Moderator
6:15PM - 6:25PM
Merrick I. Ross, MD, FACS
Great Debate-Pancreas Cancer: Neoadjuvant vs Adjuvant Old Controversy with New Insights - Pro Neo
6:27PM - 6:39PM
Matthew H. Katz, MD
Great Debate-Pancreas Cancer: Neoadjuvant vs Adjuvant Old Controversy with New Insights - Pro Adj
6:39PM - 6:51PM
Jordan Cloyd, MD
Pathological Response Reporting
6:51PM - 7:03PM
Michael Tetzlaff, MD

Head and Neck Cancer
7:03PM - 7:15PM
Neil D. Gross, MD

Gastric Cancer
7:15PM - 7:27PM
Brian D. Badgwell, MD

 
2ND ANNUAL MICHAEL FRUMOVITZ MEMORIAL LECTURE

Managing Rare Gynecological Malignancies
7:27PM - 7:45PM
Aaron Shafer, MD

 
WELCOME RECEPTION

Welcome Reception & Networking Opportunity
8:00PM - 10:00PM


Location: Mountain View Terrace
Saturday, January 17, 2026
 
SESSION 5: THORACIC ONCOLOGY

MODERATOR: Stephen Swisher
Metastatic Non-Small Cell Lung Cancer: Best of 2025
7:00AM - 7:25AM
John V. Heymach, MD
Session 5 - Moderator
7:00AM - 7:10AM
Stephen G. Swisher, MD
Recent Advances in Perioperative/Neoadjuvant Therapy for Resectable NSCLC
7:25AM - 7:40AM
Don L. Gibbons, MD

Surgical Decision-Making for the Treatment of Oligo-Metastatic Lung Cancer
7:40AM - 7:55AM
David C. Rice, MD

New Insights in the Multi-Disciplinary Management of Small Cell Carcinoma?
7:55AM - 8:10AM
Quynh Nhu Nguyen, MD
Advances in the Multimodality Management of Esophageal Cancer
8:10AM - 8:25AM
Wayne L. Hofstetter, MD

Panel Q & A and Case Presentation/Panel Discussion
8:25AM - 9:30AM


Panel: All Speakers


 
SESSION 6: GI AND HEPATOBILIARY ONCOLOGY

MODERATOR: Brian Bednarski
Session 6 - Moderator
4:30PM - 4:40PM
Brian K. Bednarski, MD
The Natural History and Management of Cystic Neoplasms of the Pancreas
4:30PM - 4:45PM
Michael P. Kim, MD
Radiation Therapy for Oligometastatic GI Liver Metastases
4:45PM - 5:00PM
Eugene J. Koay, MD
Using Radiation to Overcome Checkpoint Resistance from Liver Metastases
5:00PM - 5:15PM
James Welsh, MD

Histotripsy: Recent Results and Future Directions
5:15PM - 5:30PM
Hop S. Tran Cao, MD, FACS
Patient Selection for Non-Operative Therapy for Rectal Cancer
5:30PM - 5:45PM
Brian K. Bednarski, MD
Evolving Indications for HIPEC for Colon-Rectal Cancer
5:45PM - 6:00PM
Michael G. White, MD
Update on Managing Patients with CDH-1 Mutation
6:00PM - 6:15PM
Paul F. Mansfield, MD
Panel Q & A and Case Presentation Panel Discussion
6:15PM - 7:30PM


Moderator: Brian Bednarski

Panel: All Speakers, + Tim Newhook, Albert Koong, Brian Badgwell


Sunday, January 18, 2026
 
SESSION 7: UROLOGICAL ONCOLOGY

MODERATOR: Brian Chapin
Proton Therapy for Prostate Cancer - Update of Clinical Outcomes
7:00AM - 7:20AM
Steven J. Frank, MD
Session 7 - Moderator
7:00AM - 7:10AM
Brian F. Chapin, MD
Update on Combination Immunotherapy for Metastatic Prostate Cancer
7:20AM - 7:35AM
Sumit K. Subudhi, MD

Decision Making in the Management of Small Renal Cell Tumors
7:35AM - 7:50AM
Surena F. Matin, MD
Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma
7:50AM - 8:05AM
Bradley C Leibovich, MD, FACS
Update on Multi-Modality and Neoadjuvant Therapy for Advanced Bladder Cancer
8:05AM - 8:20AM
Kelly K Bree, MD
Panel Q & A and Christopher Wood Memorial Case Presentations
8:20AM - 9:30AM


Moderator: Brian Chapin

Panel: All Speakers + Matthew Campbell, Neema Navai, and Justin Gregg


 
SESSION 8: BREAST ONCOLOGY

MODERATOR: Kelly Hunt
Personalizing Breast Cancer Surgery: Update on Axillary Surgery for Patients with Positive Nodes: TAD? Dissection? Or No Surgery
4:30PM - 4:50PM
Rosa F. Hwang, MD, FACS

Session 8 - Moderator
4:30PM - 4:40PM
Kelly K. Hunt, MD
Personalizing Breast Cancer Surgery: New Technologies to Reduce Positive Margin Rates in Breast Conserving Surgery
4:50PM - 5:05PM
Kelly K. Hunt, MD

Personalizing Breast Cancer Surgery: Selective Approach to Non-Operative Management of Early-Stage Breast Cancer
5:05PM - 5:25PM
Kelly K. Hunt, MD

Personalizing Breast Cancer Surgery: Decision Making for Adjuvant XRT after Breast Conserving Surgery: Whole Breast, Proton, Partial, or Omission?
5:25PM - 5:45PM
Michael C. Stauder, MD

Advances in Systemic Therapy - The Best of 2025 - Part 1: Triple Negative Breast Cancer
5:45PM - 6:05PM
Jennifer K. Litton, MD

Advances in Systemic Therapy - The Best of 2025 - Part 2: HER2 and Hormone Receptor Positive Breast Cancer
6:05PM - 6:25PM
Sharon H. Giordano, MD, FASCO

Panel Q & A and Case Presentations
6:25PM - 7:30PM


Moderators: Kelly Hunt and Rosa Hwang

Panel: All Speakers, + Funda Meric-Bernstam, Lavinia Middleton


Monday, January 19, 2026
 
SESSION 9: CUTANEOUS ONCOLOGY

MODERATOR: Merrick Ross
Melanoma: Best of 2025
7:00AM - 7:20AM
Sapna Patel, MD

Session 9 - Moderator
7:00AM - 7:10AM
De-Escalation of Lymphadenectomy after Neoadjuvant Therapy for Advanced Stage III Melanoma: Ready for Prime Time?
7:20AM - 7:40AM
Jeffrey E. Gershenwald, MD

Tumor Infiltrating Lymphocyte Therapy for Disseminated Melanoma: Indications, Patient Selection, and Novel Strategies
7:40AM - 7:55AM
Rodabe N. Amaria, MD

Any Progress in Treating Leptomeningeal Disease?
7:55AM - 8:10AM
Isabella C. Glitza, MD

Immunotherapy fand Oncolytic Therapy or Advanced Non-Melanoma Skin Cancer
8:10AM - 8:30AM
Michael K Wong, MD, PhD, FRCPC

Panel Q & A and Case Presentations
8:30AM - 9:30AM


Moderator: Merrick Ross

Panel: All Speakers, + Ana Ciurea, Victor Prieto, Keith Delman


Closing Remarks
9:30AM - 9:40AM
Merrick I. Ross, MD, FACS

REGISTRATION UPDATE
Thank you for your interest in the 22nd Oncology Updates: Advances and Controversies. Due to an overwhelming response, we have reached full capacity and are no longer accepting registrations.

We appreciate your support and hope that you can participate in other upcoming activities.

Thank you for your understanding.


Exhibitor Registration Requirements

  • Registration & Agreement: To participate as an exhibitor, both registration and a signed exhibit agreement are required.

  • Confirmation Process: Your exhibit is only confirmed after completing registration and submitting a fully executed agreement.

  • Payment Timeline: The signed agreement and payment must be submitted prior to the event.

  • Additional Badges: Extra exhibitor badges can only be purchased by companies with confirmed exhibitor status.

  • Support Clarification: Grant and in-kind support are independent and separate from exhibitor fees.

Click Here to View the Letter of Request


Contact Us:
Cicely A. Simon, Manager, Continuing Education
Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
PO Box 301407
Houston, TX 77230-1407
Phone: 281-813-4261
Email: [email protected]


W9 Form Exhibit at this Event

Exhibitor Packages

Exhibitor Package - Bronze Level Price: $2500.00
Includes:
  • Recognition as a Bronze Level Exhibitor
  • 6ft. Tabletop Display (Draped) with Two Chairs
  • Number of Exhibitor Badges: 2
  • Complimentary meals (available with exhibitor badge)
  • Exhibit Location: Designated Location

Deadline for order commitment is 1/2/2026 12:00:00 AM.

Exhibitor Package - Silver Level Price: $5000.00
Includes:
  • Recognition as a Silver Level Exhibitor
  • 6ft. Tabletop Display (Draped) with Two Chairs
  • Number of Exhibitor Badges: 3
  • Complimentary meals (available with exhibitor badge)
  • Exhibit Location: Designated Location

Deadline for order commitment is 1/2/2026 12:00:00 AM.

Exhibitor Package - Gold Level Price: $7500.00
Includes:
  • Recognition as a Gold Level Exhibitor
  • 6ft. Tabletop Display (Draped) with Two Chairs
  • Number of Exhibitor Badges: 4
  • Complimentary meals (available with exhibitor badge)
  • Exhibit Location: Designated Premium Location

Deadline for order commitment is 1/2/2026 12:00:00 AM.

Exhibitor Package - Platinum Level Price: $10000.00
Includes:
  • Recognition as a Platinum Level Exhibitor
  • 6ft. Tabletop Display (Draped) with Two Chairs
  • Number of Exhibitor Badges: 5
  • Complimentary meals (available with exhibitor badge)
  • Exhibit Location: Designated Premium Location

Deadline for order commitment is 1/2/2026 12:00:00 AM.

Exhibitor Package - Non-CE Satellite Symposium - Option 1: Friday, January 16, 2026 | 9:45 am - 10:30 am Price: $15000.00
Includes:
  • Recognition as a Non-CE Satellite Symposium Exhibitor
  • Number of Exhibitor Badges: 0

Deadline for order commitment is 12/29/2025 12:00:00 AM.

Exhibitor Package - Non-CE Satellite Symposium - Option 2: Friday, January 16, 2026 | 3:15 pm - 4:00 pm Price: $15000.00
Includes:
  • Recognition as a Non-CE Satellite Symposium Exhibitor
  • Number of Exhibitor Badges: 0

Deadline for order commitment is 12/29/2025 12:00:00 AM.

Exhibitor Package - Non-CE Satellite Symposium - Option 3: Saturday, January 17, 2026 | 9:45 am - 10:30 am Price: $15000.00
Includes:
  • Recognition as a Non-CE Satellite Symposium Exhibitor
  • Number of Exhibitor Badges: 0

Deadline for order commitment is 12/29/2025 12:00:00 AM.

Exhibitor Package - Non-CE Satellite Symposium - Option 4: Saturday, January 17, 2026 | 3:15 pm - 4:00 pm Price: $15000.00
Includes:
  • Recognition as a Non-CE Satellite Symposium Exhibitor
  • Number of Exhibitor Badges: 0

Deadline for order commitment is 12/29/2025 12:00:00 AM.

Exhibitor Package - Non-CE Satellite Symposium - Option 5: Sunday, January 18, 2026 | 9:45 am - 10:30 am Price: $15000.00
Includes:
  • Recognition as a Non-CE Satellite Symposium Exhibitor
  • Number of Exhibitor Badges: 0

Deadline for order commitment is 12/29/2025 12:00:00 AM.

Exhibitor Package - Non-CE Satellite Symposium - Option 6: Sunday, January 18, 2026 | 3:15 pm - 4:00 pm Price: $15000.00
Includes:
  • Recognition as a Non-CE Satellite Symposium Exhibitor
  • Number of Exhibitor Badges: 0

Deadline for order commitment is 12/29/2025 12:00:00 AM.

Exhibitor Package - 1 Additional Badge Price: $500.00
Includes:
  • Number of Exhibitor Badges: 1
  • Complimentary meals (available with exhibitor badge)

Deadline for order commitment is 1/20/2026 12:00:00 AM.

Exhibitor Package - 2 Additional Badges Price: $1000.00
Includes:
  • Number of Exhibitor Badges: 2
  • Complimentary meals (available with exhibitor badge)

Deadline for order commitment is 1/20/2026 12:00:00 AM.

Exhibitor Package - 3 Additional Badges Price: $1500.00
Includes:
  • Number of Exhibitor Badges: 3
  • Complimentary meals (available with exhibitor badge)

Deadline for order commitment is 1/20/2026 12:00:00 AM.

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
 Privacy policies   

©2023 The University of Texas MD Anderson Cancer Center
Contact Us: [email protected]

See us on Facebook See us on Twitter See us on Linked In See us on Instagram